retatrutide clinical trial phase Retatrutide: FDA approval time, results & weight loss Pharmaceutical Executive Daily: Eli Lilly

Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187

If you are pregnant or suspect pregnancy GLP-1 medications are contraindicated during pregnancy

The drug suppresses appetite and promotes satiety, possibly leading to weight loss

On one hand, a large 2024 cohort study (over 160,000 patients with obesity) reported a significantly higher incidence of new psychiatric diagnoses among GLP-1 RA users: an ~98% increase in risk of any psychiatric disorder compared to matched non-users, including a 195% higher risk of major depression and ~106% higher risk of suicidal behavior (Scientific Reports 2024)